Cargando…

Excellent Interim Treatment Response with Polatuzumab Vedotin

Detalles Bibliográficos
Autores principales:	Mehtap, Özgür, Dağlıöz Görür, Gözde, Ünal, Serkan, Gedük, Ayfer
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Galenos Publishing 2020
Materias:	Images in Hematology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7702642/ https://www.ncbi.nlm.nih.gov/pubmed/32608220 http://dx.doi.org/10.4274/tjh.galenos.2020.2020.0042

Ejemplares similares

Improvement of Cutaneous Anaplastic Large Cell Lymphoma by Brentuximab Vedotin Monotherapy
por: Onaka, Takashi, et al.
Publicado: (2018)

Polatuzumab vedotin for B-cell lymphoma
Publicado: (2020)

Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Correction to: Polatuzumab Vedotin: First Global Approval
por: Deeks, Emma D.
Publicado: (2019)

Spontaneous Remission in Paroxysmal Nocturnal Hemoglobinuria: An Extremely Rare Case
por: Mehtap, Özgür, et al.
Publicado: (2022)

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma
por: Jagadeesh, Deepa, et al.
Publicado: (2022)

Evaluation of metabolic changes in FDG PET/CT imaging after mRNA-based COVID-19 vaccination
por: İŞGÖREN, Serkan, et al.
Publicado: (2022)

Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
por: Sehn, Laurie H., et al.
Publicado: (2020)

Polatuzumab Vedotin in a Patient with Refractory Burkitt Lymphoma, a Case Report
por: Alanzi, Meshaal, et al.
Publicado: (2023)

Hereditary Elliptocytosis with Pyropoikilocytosis
por: Bayhan, Turan, et al.
Publicado: (2016)

Lysosomal Vesicles, Giant Granules, and Erythrophagocytosis in Chédiak-Higashi Syndrome
por: Beken, Burçin, et al.
Publicado: (2014)

Vacuolization in Myeloid and Erythroid Precursors in a Child with Menkes Disease
por: Sayın, Seçil, et al.
Publicado: (2019)

Retrospective Analysis With Propensity Score Matching of Peripheral T-Cell Lymphoma Treated Frontline With Brentuximab Vedotin and Chemotherapy
por: Burke, John M, et al.
Publicado: (2023)

The Side Effects of Imatinib
por: Uzer, Elmas, et al.
Publicado: (2013)

Myeloperoxidase Deficiency: The Secret Under the Flag of Unstained Cell
por: Patıroğlu, Türkan, et al.
Publicado: (2013)

Polatuzumab vedotin with infusional chemotherapy for untreated aggressive B-cell non-Hodgkin lymphomas
por: Lynch, Ryan C., et al.
Publicado: (2022)

Diagnosis: Melanoderma after Hematopoietic Stem Cell Transplantation
por: Ünal, Şule, et al.
Publicado: (2015)

Polatuzumab Vedotin for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Transplant-Ineligible Patients
por: Douglas, Melanie
Publicado: (2020)

Polatuzumab Vedotin: Current Role and Future Applications in the Treatment of Patients with Diffuse Large B-Cell Lymphoma
por: Assi, Rita, et al.
Publicado: (2021)

Integrated Two‐Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non‐Hodgkin Lymphoma
por: Lu, Dan, et al.
Publicado: (2019)

Frontline polatuzumab vedotin for diffuse large B‐cell lymphoma: A survey of clinician impressions
por: Major, Ajay, et al.
Publicado: (2022)

The molecular rationale for the combination of polatuzumab vedotin plus rituximab in diffuse large B‐cell lymphoma
por: Kawasaki, Natsumi, et al.
Publicado: (2022)

Point and counterpoint: Polatuzumab vedotin in the front-line therapy for diffuse large B- cell lymphoma
por: Thomas, Colin, et al.
Publicado: (2023)

Cost-effectiveness of polatuzumab vedotin combined with chemoimmunotherapy in untreated diffuse large B-cell lymphoma
por: Kambhampati, Swetha, et al.
Publicado: (2022)

Polatuzumab vedotin, rituximab, and bendamustine combination in relapsed or refractory diffuse large B-cell lymphoma: a real-world data from Turkey
por: Dal, Mehmet Sinan, et al.
Publicado: (2022)

Polatuzumab Vedotin for the Front-Line Treatment of Diffuse Large B-Cell Lymphoma: A New Standard of Care?
por: Davis, James A., et al.
Publicado: (2023)

Promyelocytic Blastic Crisis in Chronic Myeloid Leukemia During Imatinib Treatment
por: Angriman, Federico, et al.
Publicado: (2015)

Evaluation of a Generic Bortezomib Molecule in Newly Diagnosed Multiple Myeloma Patients
por: Mersin, Sinan, et al.
Publicado: (2021)

Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma
por: Shemesh, Colby S., et al.
Publicado: (2020)

Time‐to‐Event Analysis of Polatuzumab Vedotin‐Induced Peripheral Neuropathy to Assist in the Comparison of Clinical Dosing Regimens
por: Lu, D, et al.
Publicado: (2017)

Integrated summary of immunogenicity of polatuzumab vedotin in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma
por: Dere, Randall C., et al.
Publicado: (2023)

Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trial
por: Song, Yuqin, et al.
Publicado: (2023)

Acute Pancreatitis Induced by Polatuzumab-Vedotin-Piiq in Combination With Bendamustine and Rituximab for Diffuse Large B-Cell Lymphoma
por: Anderson, Kara, et al.
Publicado: (2020)

Results of a United Kingdom real-world study of polatuzumab vedotin, bendamustine, and rituximab for relapsed/refractory DLBCL
por: Northend, Michael, et al.
Publicado: (2022)

Polatuzumab vedotin plus bendamustine and rituximab in relapsed/refractory DLBCL: survival update and new extension cohort data
por: Sehn, Laurie H., et al.
Publicado: (2022)

Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
por: Topp, Max S., et al.
Publicado: (2022)

Profile of Polatuzumab Vedotin in the Treatment of Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: A Brief Report on the Emerging Clinical Data
por: Sawalha, Yazeed, et al.
Publicado: (2020)

P1117: GLOFITAMAB PLUS R-CHOP OR POLATUZUMAB VEDOTIN-R-CHP IS DELIVERABLE AND YIELDS HIGH OVERALL RESPONSE IN PATIENTS <=65 YEARS OF AGE WITH HIGH-RISK DLBCL OR HGBL: INTERIM ANALYSIS OF THE COALITION STUDY
por: Minson, Adrian, et al.
Publicado: (2023)

Synchronous Lymphomas: An Uncommon Affair
por: Vidhya, Manohor
Publicado: (2020)

How Does It Look in an Autopsy? Hepatosplenic T-Cell Lymphoma in a Patient with Crohn’s Disease on Azathioprine
por: Rastogi, Pulkit, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_td01j0nlhhi8ha7nlu8j9jqqek